Cargando…

p38 MAPK signaling in M1 macrophages results in selective elimination of M2 macrophages by MEK inhibition

M2 macrophages promote tumor progression and therapy resistance, whereas proimmunogenic M1 macrophages can contribute to the efficacy of cytostatic and immunotherapeutic strategies. The abundance of M2 macrophages in the immune infiltrate of many cancer types has prompted the search for strategies t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baumann, Daniel, Drebant, Jennifer, Hägele, Tanja, Burger, Luisa, Serger, Clara, Lauenstein, Claudia, Dudys, Przemyslaw, Erdmann, Gerrit, Offringa, Rienk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292803/ https://www.ncbi.nlm.nih.gov/pubmed/34285105 http://dx.doi.org/10.1136/jitc-2020-002319

Ejemplares similares

TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
por: Brauneck, Franziska, et al.
Publicado: (2022)

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
por: Baumann, Daniel, et al.
Publicado: (2020)

Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
por: Ou, Da-Liang, et al.
Publicado: (2021)

CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype
por: Li, Han, et al.
Publicado: (2022)

M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer
por: Hensler, Michal, et al.
Publicado: (2020)

CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes
por: Schroeder, Brett A, et al.
Publicado: (2021)

Targeting immune-checkpoint inhibitor resistance mechanisms by MEK inhibitor and agonist anti-CD40 antibody combination therapy
por: Baumann, Daniel, et al.
Publicado: (2020)

Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade
por: Xu, Lijun, et al.
Publicado: (2022)

GPC2 antibody–drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies
por: Pascual-Pasto, Guillem, et al.
Publicado: (2022)

Loss of ADAR1 in macrophages in combination with interferon gamma suppresses tumor growth by remodeling the tumor microenvironment
por: Lin, Weiwei, et al.
Publicado: (2023)

The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
por: Haagensen, E J, et al.
Publicado: (2012)

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer
por: Prasad, Manu, et al.
Publicado: (2022)

Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib
por: Yang, Yang, et al.
Publicado: (2020)

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma
por: Schreck, Karisa C, et al.
Publicado: (2020)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

MLL1 is central to macrophage-mediated inflammation
por: Schaller, Matthew A.
Publicado: (2023)

PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesothelioma
por: Homicsko, Krisztian, et al.
Publicado: (2023)

β-elemene regulates M1-M2 macrophage balance through the ERK/JNK/P38 MAPK signaling pathway
por: Zhou, Yingyu, et al.
Publicado: (2022)

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
por: Lau, Peter Kar Han, et al.
Publicado: (2021)

Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy
por: Kober, Christina, et al.
Publicado: (2023)

Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies
por: Larroquette, Mathieu, et al.
Publicado: (2022)

Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer
por: Zhang, Mingjie, et al.
Publicado: (2020)

Cathepsin C Is Involved in Macrophage M1 Polarization via p38/MAPK Pathway in Sudden Cardiac Death
por: Dai, Jialin, et al.
Publicado: (2021)

IMMU-22. Safely targeting GD2 in thalamic diffuse midline glioma with mRNA CAR T cells
por: Foster, Jessica, et al.
Publicado: (2022)

IMMU-31. PNOC007: H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M DIFFUSE MIDLINE GLIOMAS (DMG)
por: Mueller, Sabine, et al.
Publicado: (2020)

Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
por: Donhauser, Lara Victoria, et al.
Publicado: (2023)

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
por: Leclercq, Gabrielle, et al.
Publicado: (2022)

Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
por: Zhang, Wen, et al.
Publicado: (2022)

Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer
por: Broutin, Sophie, et al.
Publicado: (2016)

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
por: Siddiqui, Bilal A, et al.
Publicado: (2023)

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Pachynski, Russell K, et al.
Publicado: (2021)

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
por: McNeel, Douglas G, et al.
Publicado: (2022)

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)
por: Johnson, Benny, et al.
Publicado: (2022)

Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma
por: Weng, Jialei, et al.
Publicado: (2023)

Mycobacterium tuberculosis-induced expression of granulocyte-macrophage colony stimulating factor is mediated by PI3-K/MEK1/p38 MAPK signaling pathway
por: Cho, Jang-Eun, et al.
Publicado: (2013)

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
por: De Keersmaecker, Brenda, et al.
Publicado: (2020)

Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
por: Zucali, Paolo Andrea, et al.
Publicado: (2022)

Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation
por: Marquardt, Viktoria, et al.
Publicado: (2023)

Macrophage in chronic kidney disease
por: Guiteras, Roser, et al.
Publicado: (2016)

IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
por: de Billy, Emmanuel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ptctbit383lrir5rc2uc9v4kmf